$19.62
+0.11 (+0.56%)
NOV News30 articles
SLB Shares Decline Amid Oil Price Drop Despite Indonesian Gas Contract
SLB shares dropped 1.8% to $50.64 as oil prices declined, overshadowing new offshore drilling contracts for a deepwater gas project in Indonesia targeting first production by 2028.
Fundrise Innovation Fund Soars 55% in NYSE Debut as Retail Flocks to Private AI
Fundrise Innovation Fund shares skyrocketed 54.5% to $117.70 in their second day of NYSE trading, valuing the fund at more than six times its March 2 net asset value. The closed-end fund provides retail access to private artificial intelligence companies.
Novo Nordisk Shares Dip Despite FDA Nod for Higher-Dose Wegovy
Novo Nordisk shares declined in Copenhagen trading even after U.S. regulators cleared a higher-dose version of its Wegovy obesity treatment. Competitive pressures from Eli Lilly and looming generic competition in India weighed on investor sentiment.
Hims & Hers Stock Stabilizes as Novo Deal Shifts Focus to Profitability
Hims & Hers Health shares traded near $23.82 Friday, stabilizing after a week of volatility driven by its new branded obesity drug agreement with Novo Nordisk. The shift from compounded medications raises margin concerns despite reducing regulatory risk.
Cenovus Energy Reaches 52-Week Peak Amid Oil Supply Fears
Cenovus Energy shares climbed 4.6% to C$32.18, hitting a 52-week high as crude prices neared $100 a barrel. The company projects 2026 upstream output could reach 985,000 barrels of oil equivalent per day.
Cenovus Energy Reaches 52-Week Peak Amid Oil Price Surge
Cenovus Energy shares surged to a 52-week high as Brent crude oil prices topped $100 per barrel, driven by renewed Middle East conflicts. The company's significant debt and planned operational turnarounds underscore its exposure to volatile energy markets.
Hims & Hers Stock Extends Rally on Novo Nordisk Patent Settlement
Shares of Hims & Hers Health continued their ascent following a resolution to a patent conflict with Novo Nordisk, which will reintroduce branded GLP-1 medications to its service. Analysts have upgraded the stock but caution about potential margin pressures.
Hims & Hers Soars on Novo Nordisk Partnership, Analyst Targets Rise
Shares of Hims & Hers Health skyrocketed approximately 49% over two sessions following a new distribution agreement with Novo Nordisk. The deal resolves a legal dispute and will bring branded GLP-1 drugs to the telehealth platform, leading several analysts to raise their price targets.
GE Vernova Commits $200M to Vietnam Transformer Plant Amid Energy Push
GE Vernova will invest approximately $200 million to establish a large power transformer plant in Hai Phong, Vietnam, with full operations targeted for 2028. The move aligns with Vietnam's accelerated LNG and grid infrastructure development.
Hims & Hers Shares Jump on Novo Nordisk Partnership Revival
Hims & Hers Health shares surged in premarket trading Monday following reports that Novo Nordisk will resume selling its weight-loss drugs through the telehealth platform. The move marks a reversal from a patent dispute last month.
GE Vernova Secures Major Italian Wind Contract, Expands Grid Component Plant
GE Vernova has secured a contract to supply 17 onshore wind turbines for a project in southern Italy, with deliveries starting in 2027. Concurrently, the company is investing $30 million to expand its electrification component plant near Milan.
GE Vernova Gains on Italian Wind Deal and $30M Grid Plant Investment
GE Vernova's stock advanced following new Italian contracts for wind turbines and grid equipment, alongside a $30 million manufacturing expansion near Milan.
FDA Issues Second Ozempic Ad Warning to Novo Nordisk in Escalating Scrutiny
The FDA has sent Novo Nordisk a second advertising violation notice in under a month, citing misleading claims for Ozempic. The agency simultaneously warned 30 telehealth companies about compounded GLP-1 drug promotions.
GE Vernova Shares Slide 5% Amid Broad Market Sell-Off
GE Vernova shares declined approximately 5% on Tuesday, underperforming a broader market downturn. The power equipment firm detailed a $30 million expansion in Italy and finalized the sale of its Proficy software unit.
GE Vernova Dips Amid Inflation, Fed Focus; Wind Project Risks Loom
GE Vernova stock declined slightly Friday as broader markets fell on higher-than-expected wholesale inflation. Investors are now focused on upcoming jobs data and Federal Reserve signals.
Hims & Hers Faces SEC Probe, Novo Nordisk Lawsuit as Analysts Cut Targets
Hims & Hers Health shares held steady premarket following disclosures of an SEC probe and a patent lawsuit from Novo Nordisk. Analysts at BTIG and Citi downgraded the stock, citing regulatory risks.
GE Vernova Shares Dip Ahead of Holiday, Wind Losses Offset Grid Demand
GE Vernova shares declined 1.77% to $802.13 on Friday, retreating from recent highs ahead of the Presidents Day market closure. The company balances robust orders for gas turbines and grid infrastructure with persistent challenges in its wind segment.
GE Vernova Shares Pull Back After Recent High, Wind Losses Weigh
GE Vernova shares declined nearly 2% Friday, retreating from a 52-week high. The company's wind business reported a significant EBITDA loss for 2025, with more losses projected.
NovaGold Shares Retreat After Sharp Rally as Donlin Feasibility Study Progresses
NovaGold Resources shares declined 1.4% in premarket trading following a 12.7% surge, with investor attention fixed on the Donlin Gold feasibility study and recent capital raises.
NovoCure Shares Surge on FDA Approval for Pancreatic Cancer Device
NovoCure's stock jumped over 20% premarket after the FDA cleared its Optune Pax device for treating locally advanced pancreatic cancer, marking the first new treatment for this condition in nearly three decades.
GE Vernova Surges on Long-Term Turbine Reservation Agreement
GE Vernova shares advanced over 4% after Maxim Power secured a 2030 delivery slot for a gas turbine, signaling strong future demand. Trading volume exceeded 2.7 million shares.
Novelis Targets June Restoration for Fire-Damaged Oswego Plant as Q3 Loss Hits $160M
Novelis posted a $160 million Q3 loss after fires disrupted its Oswego aluminum plant, cutting shipments 11%. Repairs aim for June completion, but Ford warns full output may not resume until September, pressuring F-150 costs.
Hims & Hers Shares Stabilize After Novo Nordisk Patent Lawsuit Rattles Weight-Loss Strategy
Hims & Hers stock edged up 0.1% premarket following steep declines after Novo Nordisk filed a patent lawsuit over compounded semaglutide. Investors await court developments, FDA signals, and the company's Feb. 23 earnings.
GE Vernova Shares Dip on Long-Term Turbine Reservation, Investors Eye Earnings
GE Vernova's stock declined slightly as Maxim Power secured a 2030 gas turbine slot, with attention turning to the company's upcoming quarterly earnings report.
Hims & Hers Shares Extend Decline Amid Novo Nordisk Patent Lawsuit Over Compounded Weight-Loss Drugs
Hims & Hers Health stock fell another 5.6% as Novo Nordisk filed a patent lawsuit seeking to block compounded versions of Wegovy, tightening regulatory pressure on the online health provider's GLP-1 offerings.
GE Vernova Shares Reach Record High on Long-Term Turbine Reservation
GE Vernova's stock surged to a new peak after Maxim Power secured a 2030 manufacturing slot for a gas turbine, with analysts raising price targets amid a growing equipment backlog.
Hims & Hers Shares Plunge 16% After Halting $49 Weight-Loss Pill Amid Novo Nordisk Lawsuit
Hims & Hers Health stock tumbled in after-hours trading following the withdrawal of its compounded semaglutide product and a patent infringement lawsuit from Novo Nordisk. Leerink Partners reduced its price target on the company.
GE Vernova Shares Gain on Long-Term Turbine Reservation and UK Plant Upgrade
GE Vernova stock rose 3.6% after securing a turbine slot reservation for a 2030 delivery and completing an efficiency upgrade at a UK power plant, highlighting strong demand for long-cycle energy equipment.
Novo Nordisk Shares Surge as Hims Abandons Low-Cost Semaglutide Pill
Novo Nordisk stock climbed over 8% after Hims & Hers canceled plans for a $49 compounded weight-loss pill. The move follows FDA warnings against unapproved GLP-1 drug marketing.
Novo Nordisk Rebounds as FDA Vows Crackdown on Wegovy Copycats
Novo Nordisk B shares surged 5.29% after Hims & Hers halted its $49 compounded version of Wegovy, with the FDA pledging action against unauthorized copycats. The stock remains down roughly 20% over five sessions amid pricing uncertainty.